Director at aTYR Pharma (ATYR) receives 50,000-share stock option grant

Rhea-AI Filing Summary

aTYR Pharma director Eric Benevich received a new stock option grant. On May 11, 2026, he was awarded options to buy 50,000 shares of aTYR Pharma common stock at an exercise price of $0.95 per share. These options were granted under the company’s non-employee director compensation policy.

The option vests in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues serving on the Board of Directors. Following this grant, he holds 50,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider BENEVICH ERIC

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	50,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 50,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 50,000 options Exercise price: $0.95 per share Underlying shares: 50,000 shares +3 more

6 metrics

Option grant size 50,000 options Stock Option (right to buy) granted May 11, 2026

Exercise price $0.95 per share Conversion/exercise price for the 50,000 options

Underlying shares 50,000 shares Common stock underlying the stock option grant

Post-grant options held 50,000 options Total derivative securities following the transaction

Option expiration May 11, 2036 Expiration date of the stock option grant

Vesting date trigger Earlier of May 11, 2027 or 2027 meeting Vesting condition subject to continued Board service

Key Terms

Stock Option (right to buy), non-employee director compensation policy, vests in full, Annual Meeting of Stockholders, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

non-employee director compensation policy financial

"The option, granted pursuant to the Issuer's non-employee director compensation policy"

vests in full financial

"The option ... vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting"

Annual Meeting of Stockholders financial

"the Issuer's 2027 Annual Meeting of Stockholders"

derivative securities financial

"derivativeTransactionCount: 1, reflecting derivative securities (stock options)"

Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BENEVICH ERIC

(Last) (First) (Middle)

10240 SORRENTO VALLEY ROAD

SUITE 300

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
aTYR PHARMA INC [ ATYR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$0.95	05/11/2026		A		50,000		(1)	05/11/2036	Common Stock	50,000	$0.00	50,000	D

Explanation of Responses:

1. The option, granted pursuant to the Issuer's non-employee director compensation policy, vests in full on the earlier of (i) May 11, 2027 or (ii) the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continued service on the Board of Directors.

	/s/ Nancy E. Denyes, as Attorney-in-Fact	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did aTYR Pharma (ATYR) director Eric Benevich report in this Form 4?

Eric Benevich reported receiving a stock option grant for 50,000 shares of aTYR Pharma common stock. The options were awarded as part of the non-employee director compensation policy and give him the right to buy shares at a fixed exercise price of $0.95.

How many aTYR Pharma (ATYR) shares are covered by Eric Benevich’s new option grant?

The new option grant covers 50,000 shares of aTYR Pharma common stock. These are derivative securities, meaning they are rights to buy shares in the future rather than shares owned today, subject to vesting conditions and an exercise price of $0.95.

What is the exercise price and expiration date of Eric Benevich’s aTYR Pharma options?

The options have an exercise price of $0.95 per share and expire on May 11, 2036. This means he may choose to buy up to 50,000 shares at $0.95 any time after vesting and before the expiration date, subject to plan terms.

When do Eric Benevich’s aTYR Pharma (ATYR) options vest?

The options vest in full on the earlier of May 11, 2027 or the company’s 2027 Annual Meeting of Stockholders. Vesting is conditional on his continued service on the Board of Directors through that date, consistent with the director compensation policy.

How many aTYR Pharma derivative securities does Eric Benevich hold after this transaction?

After this transaction, Eric Benevich holds 50,000 stock options relating to aTYR Pharma common stock. These options were all acquired in this grant and represent his reported derivative position in this filing, held directly under the non-employee director compensation arrangement.

Is Eric Benevich’s Form 4 transaction a market purchase or sale of aTYR Pharma shares?

The Form 4 reports a grant of stock options, not a market purchase or sale of shares. Code “A” indicates a grant or award, so this reflects compensation in the form of options, rather than buying or selling common stock in the open market.